Richard Fleming
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Richard Fleming has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Naveed Sattar
University Departments of Obstetrics and Gynecology and Vascular Biochemistry, Royal Infirmary, Glasgow, United Kingdom G31 2ER
2 shared publicationsDaniel Ling
Paediatric Research Laboratory, Massachusetts General Hospital for Children and Harvard Medical School, Boston, Massachusetts
1 shared publication- David B. Seifer
Yale School of Medicine, New Haven, USA
1 shared publication David T. MacLaughlin
Paediatric Research Laboratory, Massachusetts General Hospital for Children and Harvard Medical School, Boston, Massachusetts
1 shared publicationÉadaoin M. Timmins
1 shared publication- Jane Elizabeth Norman
University of Bristol, Bristol, UK
1 shared publication
Latest Publications
- 1 January 2006
- Published by Taylor & Francis in Human Fertility
- Vol. 9 (2) , 101-105
Management of obese women in assisted conception units: A UK survey
A national audit was performed to ascertain details of the management of clinically obese women at infertility clinics in the UK. This was with particular reference to body mass index (BMI) limits for specific treatments and general advice given to patients regarding obesity. A postal questionnaire was sent to all licensed assisted conception units (ACUs) in the UK offering fertility treatment. The return rate was 86 of 100 (86%). There was a great deal of variation between different units in the practice standards of obese infertile women. This audit demonstrates the wide variation in current UK practice and highlights the need for a broad discussion and adoption of national guidelines for the management of obese infertile women.
- 1 January 2006
- Published by Taylor & Francis in Human Fertility
- Vol. 9 (2) , 101-105
Management of obese women in assisted conception units: A UK survey
A national audit was performed to ascertain details of the management of clinically obese women at infertility clinics in the UK. This was with particular reference to body mass index (BMI) limits for specific treatments and general advice given to patients regarding obesity. A postal questionnaire was sent to all licensed assisted conception units (ACUs) in the UK offering fertility treatment. The return rate was 86 of 100 (86%). There was a great deal of variation between different units in the practice standards of obese infertile women. This audit demonstrates the wide variation in current UK practice and highlights the need for a broad discussion and adoption of national guidelines for the management of obese infertile women.
- Open Access
- 1 August 2005
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 90 (8) , 4593-4598
Metformin and Weight Loss in Obese Women with Polycystic Ovary Syndrome: Comparison of Doses
Context: Metformin treatment of women with polycystic ovary syndrome (PCOS) is widespread, as determined by studies with diverse patient populations. No comparative examination of weight changes or metabolite responses to different doses has been reported. Objective: The aim of this study was to determine whether different doses of metformin (1500 or 2550 mg/ d) would have different effects on body weight, circulating hormones, markers of inflammation, and lipid profiles. Design: The study included prospective cohorts randomized to two doses of metformin. Setting: The study was performed at a university teaching hospital with patients from gynecology/endocrinology clinics. Patients: The patients studied were obese (body mass index, 30 to 2; n = 42) and morbidly obese (body mass index, ≥37 kg/m2; n = 41) women with PCOS. Intervention: Patients were randomized to two doses of metformin, and parameters were assessed after 4 and 8 months. Main Outcome Measures: The main outcome measures were changes in body mass, circulating hormones, markers of inflammation, and lipid profiles. Results: Intention to treat analyses showed significant weight loss in both dose groups. Only the obese subgroup showed a dose relationship (1.5 and 3.6 kg in 1500- and 2550-mg groups, respectively; P = 0.04). The morbidly obese group showed similar reductions (3.9 and 3.8 kg) in both groups. Suppression of androstenedione was significant with both metformin doses, but there was no clear dose relationship. Generally, beneficial changes in lipid profiles were not related to dose. Conclusion: Weight loss is a feature of protracted metformin therapy in obese women with PCOS, with greater weight reduction potentially achievable with higher doses. Additional studies are required to determine whether other aspects of the disorder may benefit from the higher dose of metformin.
- 1 August 2005
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 90 (8) , 4593-4598
Open AccessMetformin and Weight Loss in Obese Women with Polycystic Ovary Syndrome: Comparison of Doses
Context: Metformin treatment of women with polycystic ovary syndrome (PCOS) is widespread, as determined by studies with diverse patient populations. No comparative examination of weight changes or metabolite responses to different doses has been reported. Objective: The aim of this study was to determine whether different doses of metformin (1500 or 2550 mg/ d) would have different effects on body weight, circulating hormones, markers of inflammation, and lipid profiles. Design: The study included prospective cohorts randomized to two doses of metformin. Setting: The study was performed at a university teaching hospital with patients from gynecology/endocrinology clinics. Patients: The patients studied were obese (body mass index, 30 to 2; n = 42) and morbidly obese (body mass index, ≥37 kg/m2; n = 41) women with PCOS. Intervention: Patients were randomized to two doses of metformin, and parameters were assessed after 4 and 8 months. Main Outcome Measures: The main outcome measures were changes in body mass, circulating hormones, markers of inflammation, and lipid profiles. Results: Intention to treat analyses showed significant weight loss in both dose groups. Only the obese subgroup showed a dose relationship (1.5 and 3.6 kg in 1500- and 2550-mg groups, respectively; P = 0.04). The morbidly obese group showed similar reductions (3.9 and 3.8 kg) in both groups. Suppression of androstenedione was significant with both metformin doses, but there was no clear dose relationship. Generally, beneficial changes in lipid profiles were not related to dose. Conclusion: Weight loss is a feature of protracted metformin therapy in obese women with PCOS, with greater weight reduction potentially achievable with higher doses. Additional studies are required to determine whether other aspects of the disorder may benefit from the higher dose of metformin.
- 1 January 2005
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 10, 55-59
Recruitment prior to ovarian stimulation: ways of improving follicular recruitment
- 1 January 2005
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 10, 55-59
Recruitment prior to ovarian stimulation: ways of improving follicular recruitment
- 1 January 2005
- Published by Elsevier in Fertility and Sterility
- Vol. 83 (1) , 130-136
Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment
- 1 January 2005
- Published by Elsevier in Fertility and Sterility
- Vol. 83 (1) , 130-136
Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment
- Open Access
- 1 August 2000
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 15 (8) , 1667-1671
Fourier transform infrared spectroscopy of follicular fluids from large and small antral follicles
Fourier transform infrared spectroscopy (FTIR) was used to obtain `biochemical fingerprints' for the constitution of follicular fluids from large and small antral luteinized follicles (n = 54 pairs). All samples gave reproducible characteristic biological infrared absorption spectra, with recognizable amide I protein vibrations and acyl vibrations from fatty acids. Discriminant function analysis of the first derivative FTIR spectra, together with hierarchical cluster analysis used to construct a dendrogram, showed fluid from large follicles formed a homogeneous closely related cluster, whilst that from small follicles was distinct from the large, and heterogeneous in nature. The large follicle fluids showed closer biochemical similarity to each other than to the corresponding fluid taken from small matched follicles. An artificial neural network was trained and following validation with an independent test set, successfully distinguished follicular fluids from large and small follicles. The sex steroid concentrations in the fluids from large and small follicles were significantly different. These results show that fluid from large follicles is distinct in biochemical nature from that from small follicles, but the degree of homogeneity implies size-specific changes take place. These may have consequences for the developmental potential of the oocyte.
- 1 August 2000
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 15 (8) , 1667-1671
Open AccessFourier transform infrared spectroscopy of follicular fluids from large and small antral follicles
Fourier transform infrared spectroscopy (FTIR) was used to obtain `biochemical fingerprints' for the constitution of follicular fluids from large and small antral luteinized follicles (n = 54 pairs). All samples gave reproducible characteristic biological infrared absorption spectra, with recognizable amide I protein vibrations and acyl vibrations from fatty acids. Discriminant function analysis of the first derivative FTIR spectra, together with hierarchical cluster analysis used to construct a dendrogram, showed fluid from large follicles formed a homogeneous closely related cluster, whilst that from small follicles was distinct from the large, and heterogeneous in nature. The large follicle fluids showed closer biochemical similarity to each other than to the corresponding fluid taken from small matched follicles. An artificial neural network was trained and following validation with an independent test set, successfully distinguished follicular fluids from large and small follicles. The sex steroid concentrations in the fluids from large and small follicles were significantly different. These results show that fluid from large follicles is distinct in biochemical nature from that from small follicles, but the degree of homogeneity implies size-specific changes take place. These may have consequences for the developmental potential of the oocyte.